CAR T-cell immunotherapy of MET-expressing malignant mesothelioma

Targeting of Aberrant αvβ6 Integrin Expression in Solid Tumors Using Chimeric Antigen Receptor-Engineered T Cells

(2017) Lynsey M. Whilding et al.   MOLECULAR THERAPY

The role of the HGF/Met axis in mesothelioma

(2016) Thivyan Thayaparan et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet?

(2016) Giuseppe Bronte et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Immunotherapy for malignant mesothelioma: reality check

(2016) Bibhusal Thapa et al.   Expert Review of Anticancer Therapy

A regional approach for CAR T-cell therapy for mesothelioma: from mouse models to clinical trial

(2016) Marissa Mayor et al.   Immunotherapy

Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy

(2016) Mark O'Hara et al.   Immunotherapy

Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition

(2016) Leonid Cherkassky et al.   JOURNAL OF CLINICAL INVESTIGATION

Direct binding of hepatocyte growth factor and vascular endothelial growth factor to CD44v6

(2015) Y. Volz et al.   BIOSCIENCE REPORTS

Depleting MET-Expressing Tumor Cells by ADCC Provides a Therapeutic Advantage over Inhibiting HGF/MET Signaling

(2015) A. Hultberg et al.   CANCER RESEARCH

Syndecan-1 alters heparan sulfate composition and signaling pathways in malignant mesothelioma

(2015) Ghazal Heidari-Hamedani et al.   CELLULAR SIGNALLING

Hepatocyte Growth Factor Receptor c-Met Instructs T Cell Cardiotropism and Promotes T Cell Migration to the Heart via Autocrine Chemokine Release

(2015) Izabela Komarowska et al.   IMMUNITY

4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors

(2015) Adrienne H Long et al.   NATURE MEDICINE

Identification of Chimeric Antigen Receptors That Mediate Constitutive or Inducible Proliferation of T Cells

(2015) M. J. Frigault et al.   Cancer Immunology Research

Multifactorial T-cell Hypofunction That Is Reversible Can Limit the Efficacy of Chimeric Antigen Receptor-Transduced Human T cells in Solid Tumors

(2014) E. K. Moon et al.   CLINICAL CANCER RESEARCH

Synergistic Activity of the c-Met and Tubulin Inhibitor Tivantinib (ARQ197) with Pemetrexed in Mesothelioma Cells

(2014) Leticia Leon et al.   CURRENT DRUG TARGETS

Retargeting of Human T Cells to Tumor-Associated MUC1: The Evolution of a Chimeric Antigen Receptor

(2014) S. Wilkie et al.   JOURNAL OF IMMUNOLOGY

MET and PI3K/mTOR as a Potential Combinatorial Therapeutic Target in Malignant Pleural Mesothelioma

(2014) Rajani Kanteti et al.   PLoS One

Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity

(2014) P. S. Adusumilli et al.   Science Translational Medicine

Preclinical In Vivo Modeling of Cytokine Release Syndrome Induced by ErbB-Retargeted Human T Cells: Identifying a Window of Therapeutic Opportunity?

(2013) S. J. C. van der Stegen et al.   JOURNAL OF IMMUNOLOGY

Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells

(2013) Petra C Schuberth et al.   Journal of Translational Medicine

Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies

(2013) G. L. Beatty et al.   Cancer Immunology Research

Heparan Sulfate: A Ubiquitous Glycosaminoglycan with Multiple Roles in Immunity

(2013) David Anak Simon Davis et al.   Frontiers in Immunology

Immunity and malignant mesothelioma: From mesothelial cell damage to tumor development and immune response-based therapies

(2012) Valerio Izzi et al.   CANCER LETTERS

The proteoglycan repertoire of lymphoid cells

(2012) Bodil Fadnes et al.   GLYCOCONJUGATE JOURNAL

Dual Targeting of ErbB2 and MUC1 in Breast Cancer Using Chimeric Antigen Receptors Engineered to Provide Complementary Signaling

(2012) Scott Wilkie et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Plasma Cell Membrane Localization of c-MET Predicts Longer Survival in Patients with Malignant Mesothelioma: A Series of 157 Cases from the MESOPATH Group

(2012) Guénaëlle Levallet et al.   Journal of Thoracic Oncology

Unknown

(2012) David Davies et al.   MOLECULAR MEDICINE

Cell Membrane–associated Heparan Sulfate Is a Receptor for Prototype Foamy Virus in Human, Monkey, and Rodent Cells

(2012) Md Nasimuzzaman et al.   MOLECULAR THERAPY

Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells

(2012) Christopher C Kloss et al.   NATURE BIOTECHNOLOGY

The natural history of untreated squamous cell carcinoma of the head and neck: how we do it

(2011) J.-P. Jeannon et al.   CLINICAL OTOLARYNGOLOGY

Protein Engineered Variants of Hepatocyte Growth Factor/Scatter Factor Promote Proliferation of Primary Human Hepatocytes and in Rodent Liver

(2011) Jacob Ross et al.   GASTROENTEROLOGY

Heparan Sulfate Modification of the Transmembrane Receptor CD47 Is Necessary for Inhibition of T Cell Receptor Signaling by Thrombospondin-1

(2011) Sukhbir Kaur et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Engineering hepatocyte growth factor fragments with high stability and activity as Met receptor agonists and antagonists

(2011) Douglas S. Jones et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Selective Expansion of Chimeric Antigen Receptor-targeted T-cells with Potent Effector Function using Interleukin-4

(2010) Scott Wilkie et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells

(2009) Koji Kawaguchi et al.   CARCINOGENESIS